Document:

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

 

This First
Amendment to Employment Agreement (this “Amendment”) is made and entered as of this 30th
day of April, 2013, (the “Amendment Effective Date”) by and between Jefferson Electric, Inc., a Delaware
corporation (the “Company”), and Thomas Klink (“Executive”) for purposes of
amending that certain Employment Agreement dated as of April 30, 2010, by and between the Company and Executive (the “Agreement”).
Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed
to such terms in the Agreement.

 

WHEREAS, the
Employment Period under the Agreement is scheduled to terminate on the date hereof and the Company and Executive desire to extend
such Employment Period for three (3) additional years, unless terminated earlier in accordance with Section 6 of the Agreement;

 

WHEREAS, in
connection with such extension of the Employment Period, the Company and Executive desire to adjust Executive’s base salary
as set forth in this Amendment; and

 

WHEREAS, Section
17 of the Agreement provides that the parties to the Agreement may amend the Agreement in a writing signed by the parties.

 

NOW THEREFORE,
pursuant to Section 17 of the Agreement, and for good and valuable consideration, the sufficiency of which is hereby acknowledged,
the Company and Executive agree as follows:

 

1.           Section 1 of
the Agreement is hereby amended as of the Amendment Effective Date by deleting said section in its entirety and substituting in
lieu thereof the following new Section 1:

 

1.Employment;
Term. The Company shall employ Executive, and Executive shall work for the Company, for a term of six (6) years commencing
on the date hereof (April 30, 2010) and ending on April 30, 2016, unless terminated earlier in accordance with Section 6 hereof
(the "Employment Period").

 

2.           Section 4.1 of
the Agreement is hereby amended as of the Amendment Effective Date by deleting said section in its entirety and substituting in
lieu thereof the following new Section 4.1:

 

4.1.In consideration
for the services to be performed by Executive during the Employment Period hereunder, the Company shall pay to Executive a base
salary at the rate of $312,000 per annum for the period of May 1, 2010 through April 30, 2013 and $250,000 per annum for the period
of May 1, 2013 through April 30, 2016, payable in accordance with the Company's customary payroll practices for executive employees.

 

3.           Except as expressly
amended by this Amendment, the Agreement shall continue in full force and effect in accordance with the provisions thereof.

 

4.           In the event
of a conflict between the Agreement and this Amendment, this Amendment shall govern.

 

* * * * * * * * * *

 

[Remainder of Page Intentionally Left
Blank

Signature Page Follows.]

 

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Amendment as of the Amendment Effective Date.

  

	 	 	THE COMPANY:
	 	 	 	 
	 	 	JEFFERSON ELECTRIC, INC.
	 	 	 	 
	 	 	By	/s/ Nathan Mazurek                               
	 	 	Name:	Nathan Mazurek
	 	 	Title:	Chief Executive Officer
	 	 	 	 
	 	 	 	 
	 	 	EXECUTIVE:
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	/s/ Thomas Klink                                               
		 	Thomas KlinkExhibit 4.20.2

 

PROMISSORY NOTES COMBINED FOURTH EXTENSION
AGREEMENT

 

This Promissory Notes
Combined Fourth Extension Agreement, hereinafter referred to as “Fourth Extension Agreement”, entered into this Twenty
Fourth day of November, 2012, by and among GLOBALWISE INVESTMENT, INC. hereinafter called “Maker” and Ramon M. Shealy,
hereinafter called “Lender”.

 

WHEREAS, Maker and
Lender have entered into a Promissory Notes dated March 29, 2012 for the amount of Two Hundred Thirty Eight thousand Dollars ($238,000)
and April 16, 2012 for the amount of Twelve thousand Dollars ($12,000). Both Notes were originally due ninety days from its issuance.
An extension of the $238,000 Note was executed on June 27, 2012 for an additional sixty days to August 27, 2012. An extension of
said Note was executed for the second time on August 27, 2012 for an additional sixty days to October 25, 2012. An extension of
said Note was executed for a third time on October 24, 2012 for an additional 30 days to November 24, 2012. An extension of the
$12,000 Note was executed on July 12, 2012 for an additional sixty days to September 13, 2012. An extension of said Note was executed
for the second time on August 27th, 2012 for an additional sixty days to November 12, 2012. An extension of said Note
was executed on November 11, 2012 for 13 days to November 24, 2012.

 

WHEREAS, Maker and
Lender desire to enter into this Notes Combined Fourth Extension Agreement in order to extend the due date of both Notes to January
1, 2014.

 

NOW, THEREFORE, it
is dually agreed by both Maker and Lender to extend the due date of both said Notes to January 1st, 2014.

 

All other provisions
of the original Promissory Note shall prevail unless otherwise written.

 

IN WITNESS WHEREOF,
the undersigned Maker and Lender has duly executed this Third Extension Agreement extending the due date of the Note as of the
day and year above first written.

 

	 	GLOBALWISE INVESTMENT, INC.
	 	 
	 	By:	s/ William J. Santiago
	 	 
	 	RAMON M. SHEALY
	 	 
	 	By:	 s/ Ramon ShealyExhibit 10.1

 

AMENDMENT NO. 1 TO

SPONSORED RESEARCH AGREEMENT

 

This
Amendment No. 1 to Sponsored Research Agreement, dated April 29, 2013 (the “First Amendment”), is entered into by and
among INTERCEPT PHARMACEUTICALS, INC., a corporation organized and
existing under the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY 10013, USA (“Sponsor”),
Dipartimento di Chimica e Tecnologia del Farmaco of the Università di Perugia, Via del Liceo, 1, Perugia, Italy 06123
(“University”), and Professor Roberto Pellicciari of the Dipartimento di Chimica e Tecnologia del Farmaco at the University,
Via del Liceo, 1, Perugia, Italy 06123 (“Principal Investigator”).

 

RECITALS

 

WHEREAS, Sponsor, University and
Principal Investigator have entered into a Sponsored Research Agreement, dated as of January 1, 2012 (the “Agreement”);

 

WHEREAS, the term of the Agreement
expired on December 31, 2012; and

 

WHEREAS, the Research Parties (as
defined in the Agreement) have continued to conduct the Research Project (as defined in the Agreement) subsequent to the Term and
the parties have decided to extend such Term.

 

NOW, THEREFORE,
in consideration of the foregoing premises, INTERCEPT and Consultant hereby agree as follows:

 

ARTICLE
1: 

 

The term of the Agreement is extended for
a one year period starting on January 1, 2013 (hereinafter the “Extended Term”). For the avoidance of doubt, as used
throughout the Agreement, the term of the Agreement shall be deemed to include the Extended Term.

 

As
consideration for conducting the Research Project during the Extended Term, Sponsor agrees to fund the activities of Principal
Investigator and Project Participants under the Research Project, for which Sponsor shall pay to University a total of €80,000
during the Extended Term, payable as follows: €20,000 on March 31, 2013; €20,000 on June 30, 2013; €20,000 on September
30, 2013 and €20,000 on December 31, 2013.

 

Such payments shall cover the all services
to be rendered to the Sponsor by the University under the Agreement during the Extended Term, including the synthesis and provisioning
of Material (as defined in the Agreement) up to the quantities set forth in the material schedule to this First Amendment (the
“Material Schedule”). If Sponsor requests the delivery of Material in excess of such amounts set forth in the Material
Schedule, the parties agree to negotiate in good faith to set the additional consideration to be paid to University for such excess
quantities of Material requested by Sponsor.

 

All such payments shall be made in Euros,
the lawful currency of the European Community within fifteen (15) business days of such payment due date.

 

    	Page 1 of 3

    	 

    

 

ARTICLE
2:

 

This First Amendment shall be governed
by and construed under the laws of the State of Delaware, USA, without giving effect to the conflict of law principles thereof.

 

Any and all provisions of the Agreement
not modified hereinabove shall remain in full force and effect. All capitalized terms in this Amendment not otherwise defined shall
have the meanings ascribed to such terms in the Agreement.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

    	Page 2 of 3

    	 

    

 

In
witness whereof, the parties have executed this amendment by their proper officers as of the date first set forth above.

 

	PRINCIPAL INVESTIGATOR	 	INTERCEPT PHARMACEUTICALS, INC.
	 	 	 	 	 
	By:	/s/ Roberto Pellicciari	 	By:	/s/ Mark Pruzanski
	 	Roberto Pellicciari	 	 	Mark Pruzanski
	 	 	 	 	President and CEO

 

UNIVERSITA DI PERUGIA DIPARTIMENTO
DI CHIMICA E TECNOLOGIA DEL FARMACO

 

	By:	/s/ Benedetto Natalini	 
	Name:	 Prof. Benedetto Natalini	 
	Position:	 Director	 

 
[Signature Page – University of Perugia Amendment]

 

    	Page 3 of 3Exhibit 10.2

 

AMENDMENT NO. 1 TO

CONSULTING AND IP AGREEMENT

 

This
Amendment No. 1 to Consulting and IP Agreement, dated April 29, 2013 (the “First Amendment”), is entered into by and
between INTERCEPT PHARMACEUTICALS, INC., a corporation organized
and existing under the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY 10013, USA (“INTERCEPT”)
on the one hand and ROBERTO PELLICCIARI (“Consultant”), residing at Via U. Rocchi, 60, Perugia, Italy 06123,
on the other hand. 

 

RECITALS

 

WHEREAS, INTERCEPT and Consultant
have entered into a Consulting and IP Agreement, dated as of January 1, 2012 (the “Agreement”);

 

WHEREAS, the Term (as defined in
the Agreement) expired on December 31, 2012; and

 

WHEREAS, the Consultant has continued
to provide Services (as defined in the Agreement) subsequent to the Term and the parties have decided to extend such Term.

 

NOW, THEREFORE,
in consideration of the foregoing premises, INTERCEPT and Consultant hereby agree as follows:

 

ARTICLE
1: 

 

The Term under the Agreement is extended
for a one year period starting on January 1, 2013 (hereinafter the “Extended Term”). For the avoidance of doubt, as
used throughout the Agreement, the Term shall include the Extended Term.

 

During
the Extended Term, Consultant agrees to make himself available to render the Services, as requested
by Intercept at such times and locations as may be mutually agreed and to perform such Services in a professional and workmanlike
manner. INTERCEPT will pay to Consultant thirty thousand euros (€30,000) and seventy thousand euros (€70,000)
on an annualized basis for consulting services and IP, respectively, during the Extended Term as follows: €25,000 on March
31, 2013; €25,000 on June 30, 2013; €25,000 on September 30, 2013; and €25,000 on December 31, 2013. All such payments
shall be made in Euros, the lawful currency of the European Community within ten (10) business days of such payment due date.

 

INTERCEPT, in its sole discretion, may
extend the Term of the Agreement by one additional year by way of an amendment to the Agreement.

 

ARTICLE
2:

 

The second paragraph of Article 5.3 of
the Agreement is deleted and replaced in its entirety with the following:

 

    	Page 1 of 3

    	 

    

 

Consultant
covenants that, during the Term, (a) Consultant shall not enter into any agreement, whether written, oral or otherwise, that conflicts
with or otherwise restricts or impedes his ability to fully perform the Services or any other obligations of his under this Agreement
and (b) Consultant shall not take any action or fail to take any action with respect to any existing agreement (whether written,
oral or otherwise) or any agreement (whether written, oral or otherwise) entered into during the Term that would create a conflict
or otherwise impede his ability to fully perform the Services or any other obligations of his under this Agreement. Other than
this Agreement and another agreement with INTERCEPT regarding discovery of TGR5 agonists, Consultant hereby represents that he
is not party to any existing written or oral agreement, arrangement, understanding or other relationship pursuant to which he is
obligated to render advice and services to a commercial entity in the synthetic, computational and analytical chemistry and screening
to discover, identify, optimize and/or develop any chemical entity and/or active ingredient which is a selective or non-selective
TGR5 receptor agonist. Consultant hereby agrees and acknowledges that, during the Term of this Agreement, he will not enter into
any written or oral agreement, arrangement, understanding or other relationship pursuant to which he is obligated to render advice
and services in the synthetic, computational and analytical chemistry and screening to discover, identify, optimize and/or develop
any chemical entity and/or active ingredient which is a selective or non-selective TGR5 agonist.

 

ARTICLE
3:

 

This First Amendment shall be governed
by and construed under the laws of the State of New York, U.S., without giving effect to the conflict of law principles thereof.

 

Any and all provisions of the Agreement
not modified hereinabove shall remain in full force and effect.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

    	Page 2 of 3

    	 

    

  

In
witness whereof, the Parties have executed this amendment by their proper officers as of the date first set forth above.

 

	INTERCEPT PHARMACEUTICALS, INC.	 
	 	 	 
	/s/ Mark Pruzanski	 
	Name: Mark Pruzanski	 
	Title:	President and Chief Executive Officer	 

 

	CONSULTANT	 
	 	 
	/s/ Roberto Pellicciari	 
	Name: Roberto Pellicciari	 

 

[Signature Page – Pellicciari Consulting Agreement
(FXR)]

 

    	Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}]]